image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 6.63
-4.42 %
$ 360 M
Market Cap
-2.34
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EBS stock under the worst case scenario is HIDDEN Compared to the current market price of 6.63 USD, Emergent BioSolutions Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EBS stock under the base case scenario is HIDDEN Compared to the current market price of 6.63 USD, Emergent BioSolutions Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EBS stock under the best case scenario is HIDDEN Compared to the current market price of 6.63 USD, Emergent BioSolutions Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EBS

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.01 B REVENUE
-3.40%
-109 M OPERATING INCOME
85.04%
-191 M NET INCOME
74.94%
58.7 M OPERATING CASH FLOW
128.45%
125 M INVESTING CASH FLOW
-41.03%
-190 M FINANCING CASH FLOW
64.53%
222 M REVENUE
17.38%
49.9 M OPERATING INCOME
625.26%
68 M NET INCOME
317.25%
-11.2 M OPERATING CASH FLOW
85.98%
59.5 M INVESTING CASH FLOW
108.04%
-400 K FINANCING CASH FLOW
-80.00%
Balance Sheet Emergent BioSolutions Inc.
image
Current Assets 599 M
Cash & Short-Term Investments 99.5 M
Receivables 154 M
Other Current Assets 345 M
Non-Current Assets 791 M
Long-Term Investments 0
PP&E 271 M
Other Non-Current Assets 520 M
7.16 %11.12 %24.80 %19.47 %37.45 %Total Assets$1.4b
Current Liabilities 162 M
Accounts Payable 60.9 M
Short-Term Debt 0
Other Current Liabilities 102 M
Non-Current Liabilities 744 M
Long-Term Debt 664 M
Other Non-Current Liabilities 80.8 M
6.72 %11.19 %73.18 %8.91 %Total Liabilities$906.9m
EFFICIENCY
Earnings Waterfall Emergent BioSolutions Inc.
image
Revenue 1.01 B
Cost Of Revenue 1
Gross Profit 305 M
Operating Expenses 1.15 B
Operating Income -109 M
Other Expenses 81.9 M
Net Income -191 M
1b1b1b1b800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)(800m)(800m)(1b)(1b)1b(1)305m(1b)(109m)(82m)(191m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
30.11% GROSS MARGIN
30.11%
-10.72% OPERATING MARGIN
-10.72%
-18.80% NET MARGIN
-18.80%
-39.48% ROE
-39.48%
-13.72% ROA
-13.72%
-11.81% ROIC
-11.81%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Emergent BioSolutions Inc.
image
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -191 M
Depreciation & Amortization 109 M
Capital Expenditures -22.9 M
Stock-Based Compensation 18 M
Change in Working Capital 88.7 M
Others 210 M
Free Cash Flow 35.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Emergent BioSolutions Inc.
image
EBS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Emergent BioSolutions Inc.
image
Sold
0-3 MONTHS
49.4 K USD 1
3-6 MONTHS
261 K USD 2
6-9 MONTHS
444 K USD 2
9-12 MONTHS
0 USD 0
Bought
350 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple light bulb (Shine), a wearable promotional item (Wear), a QR code encouraging participation in the #sharenaloxone social media campaign (Share) and a box of NARCAN® Nasal Spray (Care) provided by Emergent. globenewswire.com - 1 week ago
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence. zacks.com - 2 weeks ago
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns. zacks.com - 1 month ago
Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York) Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via webcast Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference Presentation on Thursday, May 29 Jefferies Global Healthcare Conference (New York, New York) Presentation on Thursday, June 5 at 1:25 pm ETVirtual attendees can participate via webcast A replay of the presentations can be accessed from the Investors page of Emergent's website. globenewswire.com - 1 month ago
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by. seekingalpha.com - 1 month ago
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago. zacks.com - 1 month ago
Emergent BioSolutions Reports First Quarter 2025 Financial Results First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior year First Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior year First Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior year Reaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario globenewswire.com - 1 month ago
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. globenewswire.com - 1 month ago
Emergent BioSolutions Announces Stock Repurchase Program GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. globenewswire.com - 2 months ago
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). globenewswire.com - 2 months ago
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada globenewswire.com - 2 months ago
8. Profile Summary

Emergent BioSolutions Inc. EBS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 360 M
Dividend Yield 0.00%
Description Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Contact 400 Professional Drive, Gaithersburg, MD, 20879 https://www.emergentbiosolutions.com
IPO Date Nov. 15, 2006
Employees 900
Officers Mr. Richard S. Lindahl M.B.A. Executive Vice President, Chief Financial Officer & Treasurer Ms. Jessica Perl Senior Vice President, Corporate Secretary & General Counsel Mr. Joseph C. Papa Jr., M.B.A., R.Ph. Chief Executive Officer, President & Director Ms. Coleen Glessner Executive Vice President of Quality, Ethics & Compliance Ms. Stephanie Duatschek Chief Global Strategy & Franchise Development Officer Mr. Simon C. Lowry M.D. Chief Medical Officer and Head of Research & Development Mr. Paul A. Williams Senior Vice President of Products Business Mr. William Hartzel Senior Vice President of Manufacturing & Bioservices Ms. Michelle Pepin Senior Vice President & Chief Human Resource Officer